We performed a double-blind placebo-controlled study to investigate the therapeutic effect of clonidine known as alpha 2 agonist on tardive dyskinesia. Twelve out of twenty two subjects were treated with Clonidine and ten subjects were treated with placebo over 8 weeks. They were assessed by Abnormal Involuntary Movement Scale(AIMS) and symptom changes was rated by Brief Psychiatric Rating Scale (BPRS) at baseline, 4 and 8 weeks of study. The results were as follows : 1) Total AIMS scores of 8th week improved significantly, compared with those of baseline in the both clonidine group(P<0.001) and placebo group(P<0.005). 2) Total AIMS scores and face, limbs, trunk scores of the clonidine administrated group were not significantly different from those of the placebo administrated group at baseline, 4th and 8th weeks of study. 3) Most common side effect was mild dizziness, which was controlled by lowering the dose, and this clonidine adminstration study did not show any statistically significant difference between clondine and placebo group in clinical efficacy, measuring by BPRS.
서 론
대상 및 방법
결 과
고 찰
요 약
참고문헌